

## Kidney Suite Guideline Update - Committee Meeting

**Date:** 21/09/20

**Location:** Virtual

**Minutes:** Final

<b>Committee members present:</b>	
Anthony Wierzbicki (AW)	Present for notes 1 – 6
Tara Bashford (TB)	Present for notes 1 – 6
Ivan Bennett (IB)	Present for notes 1 – 6
Roy Connell (RC)	Present for notes 2 – 6
Jan Dudley (JD)	Present for notes 1 – 6
Deepa Kariyawasam (DK)	Present for notes 1 – 6
Arif Khwaja (AK)	Present for notes 2 – 6
Andrew Lewington (AL)	Present for notes 1 – 6
Fiona Loud (FL)	Present for notes 2 – 6
Rajib Pal (RP)	Present for notes 2 – 6
Catherine Pogson (CP)	Present for notes 1 – 6
Nicola Thomas (NT)	Present for notes 1 – 6

<b>In attendance:</b>		
Victoria Axe (VA)	Commissioning Manager	Present for notes 1 – 6
Steph Armstrong (SA)	Technical Analyst Health Economics	Present for notes 1 – 6
Chris Carmona (CC)	Senior Technical Analyst	Present for notes 1 – 6
Jackie Durkin (JD)	Administrator	Present for notes 1 – 6

## Kidney Suite GComm 12 minutes

Anthony Gildea (AG)	Acting Technical Analyst	Present for notes 1 – 6
Yolanda Martinez (YM)	Technical Analyst	Present for notes 1 – 6
Vonda Murray (VM)	Project Manager	Present for notes 1 – 6
Joshua Pink (JP)	Technical Adviser – Health Economics	Present for notes 1 – 6
Susan Spiers (SP)	Associate Director	Present for notes 1 – 6

### Apologies:

Clare Allinson	Committee member
Virginia Aylett	Committee member
Lucy Beggs	Technical Adviser – Health Economics
Grainne Connolly	Committee member

### 1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the 12th committee meeting on Kidney Injury & Disease. The Chair welcomed to the meeting; committee members, and NICE attendees.

The Chair introduced VM Project Manager, who provided a recap on zoom functions. The Chair thanked VM for her presentation.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Evidence review and discussion of the evidence, In adults, children and young people from black, Asian and other minority ethnic groups with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it.
- Review the recommendation for people with stage 5 CKD who are on dialysis, what amount of IV iron is most clinically and cost effective in managing anaemia and its associated outcomes.

The Chair asked all committee members to verbally declare any interests that have arisen since the last meeting. The Chair and senior members of the Developer team noted that the interests previously declared, did not prevent the attendees from fully participating in the meeting. No new interests declared.

## Kidney Suite GComm 12 minutes

<p>The Chair asked the Committee if it wanted any changes made to the minutes of GComm 11. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>
<p><b>2. RQ1.2. In adults, children and young people from black, Asian and other minority ethnic groups with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it?</b></p> <ul style="list-style-type: none"><li>• <b>Clinical evidence</b></li></ul>
<p>The Chair introduced AG Project Manager and YM, Technical Analyst, who gave a presentation on the evidence for adults, children and young people from black, Asian and other minority ethnic groups with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it. The Chair thanked AG &amp; YM for their presentation.</p>
<p><b>3. RQ1.2 In adults, children and young people from black, Asian and other minority ethnic groups with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it?</b></p> <ul style="list-style-type: none"><li>• <b>Recommendations</b></li></ul>
<p>The Chair facilitated a discussion around the review questions on adults, children and young people from black, Asian and other minority ethnic groups with CKD, what is the biological and analytical variability in eGFR testing and what factors (including fasting) affect it. The Chair thanked AG &amp; YM for their presentation.</p>
<p><b>4. RQ8.1 For people with stage 5 CKD who are on dialysis, what amount of IV iron is most clinically and cost effective in managing anaemia and its associated outcomes?</b></p> <ul style="list-style-type: none"><li>• <b>Revisit recommendations</b></li></ul>
<p>The Chair introduced CC Senior Technical Analyst, who gave a presentation about the amount of IV iron that is most clinically and cost effective in managing anaemia and its associated outcomes in people with stage 5 CKD. The Chair thanked CC for their presentation.</p>
<p><b>5. AOB</b></p>
<p>None</p>
<p><b>6. Summary and next steps</b></p>
<p>The Chair thanked the committee for their time and contribution to the meeting and reminded the committee of the date and time of the next committee meeting</p>

**Kidney Suite GComm 12 minutes**

**Date of next meeting:** 23/09/20 – 09:00 to 12:30

**Location of next meeting:** Virtual